183 related articles for article (PubMed ID: 21882135)
21. [When should anti-TNF-alpha treatment in Crohn disease be terminated?].
Moum B
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):474. PubMed ID: 20224609
[No Abstract] [Full Text] [Related]
22. [Cost effectiveness of biologicals: high costs are the other face of success].
Welsing PM; Bijl M; van Bodegraven AA; Lems WF; Prens E; Bijlsma JW
Ned Tijdschr Geneeskd; 2011; 155(29):A3026. PubMed ID: 21791128
[TBL] [Abstract][Full Text] [Related]
23. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
24. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
Sorrentino D; Fogel S; Van den Bogaerde J
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
[TBL] [Abstract][Full Text] [Related]
25. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
26. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
27. [Anti-TNF therapy and Crohn's disease].
Peyrin-Biroulet L
Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
[No Abstract] [Full Text] [Related]
28. Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens G; Diamond RH; Broussard DL; Tang KL; van der Woude CJ; Rutgeerts P;
N Engl J Med; 2010 Apr; 362(15):1383-95. PubMed ID: 20393175
[TBL] [Abstract][Full Text] [Related]
29. [Drug therapy of inflammatory bowel diseases].
Silvennoinen J; Niemelä S
Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
[No Abstract] [Full Text] [Related]
30. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
[No Abstract] [Full Text] [Related]
31. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
[No Abstract] [Full Text] [Related]
32. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
[TBL] [Abstract][Full Text] [Related]
33. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies.
Winter RW; Burakoff R
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):95-97. PubMed ID: 27900879
[No Abstract] [Full Text] [Related]
34. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease.
Sorrentino D; Terrosu G; Avellini C; Maiero S
Arch Intern Med; 2007 Sep; 167(16):1804-7. PubMed ID: 17846401
[No Abstract] [Full Text] [Related]
35. How deep is remission in perianal Crohn's disease and do imaging modalities matter?
Savoye G; Savoye-Collet C
Am J Gastroenterol; 2010 Jun; 105(6):1445-6; author reply 1446. PubMed ID: 20523317
[No Abstract] [Full Text] [Related]
36. Serpiginous choroiditis.
Cordero-Coma M; Benito MF; Hernández AM; Antolín SC; Ruíz JM
Ophthalmology; 2008 Sep; 115(9):1633, 1633.e1-2. PubMed ID: 18762076
[No Abstract] [Full Text] [Related]
37. Drug survival rates for tumour necrosis factor-α antagonists in psoriasis.
Burden AD
Br J Dermatol; 2011 May; 164(5):940-1. PubMed ID: 21518327
[No Abstract] [Full Text] [Related]
38. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
Michetti P
Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883
[No Abstract] [Full Text] [Related]
39. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
40. [Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?].
Bode M; Eder S; Schürmann G
Z Gastroenterol; 2008 Dec; 46(12):1376-83. PubMed ID: 19053007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
